Literature DB >> 3288766

The cephalosporin antimicrobial agents: a comprehensive review.

K A Caprile1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3288766     DOI： 10.1111/j.1365-2885.1988.tb00117.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN： 0140-7783            Impact factor:   1.786


× No keyword cloud information.
  9 in total

1.  Circulation of Plasmids Harboring Resistance Genes to Quinolones and/or Extended-Spectrum Cephalosporins in Multiple Salmonella enterica Serotypes from Swine in the United States.

Authors:  Ehud Elnekave; Samuel L Hong; Seunghyun Lim; Shivdeep S Hayer; Dave Boxrud; Angela J Taylor; Victoria Lappi; Noelle Noyes; Timothy J Johnson; Albert Rovira; Peter Davies; Andres Perez; Julio Alvarez
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Cefotaxime pharmacokinetics in Arabian camel (Camelus dromedarius) calves after single intravenous injection.

Authors:  Abdullah Altayban; Mahmoud Kandeel; Amin Tahoun; Mohammed Al-Nazawi
Journal:  Trop Anim Health Prod       Date:  2019-11-06       Impact factor: 1.559

3.  Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin.

Authors:  M Limbert; D Isert; N Klesel; A Markus; K Seeger; G Seibert; E Schrinner
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

Review 4.  Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Authors:  George G Zhanel; Christopher D Lawson; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Andrew Denisuik; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

5.  Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam.

Authors:  Cole L Slater; Judith Winogrodzki; Pablo A Fraile-Ribot; Antonio Oliver; Mazdak Khajehpour; Brian L Mark
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  In vitro synergistic activities of cefazolin and nisin A against mastitis pathogens.

Authors:  Kohei Kitazaki; Shoko Koga; Kohei Nagatoshi; Koichi Kuwano; Takeshi Zendo; Jiro Nakayama; Kenji Sonomoto; Hitoshi Ano; Hiromu Katamoto
Journal:  J Vet Med Sci       Date:  2017-07-29       Impact factor: 1.267

Review 7.  Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.

Authors:  Francesca De Santis; Andrea Boari; Francesco Dondi; Paolo Emidio Crisi
Journal:  Animals (Basel)       Date:  2022-01-21       Impact factor: 2.752

Review 8.  Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

Authors:  Philippe Lagacé-Wiens; Andrew Walkty; James A Karlowsky
Journal:  Core Evid       Date:  2014-01-24

Review 9.  Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

Authors:  Jose A Hidalgo; Celeste M Vinluan; Nishaal Antony
Journal:  Drug Des Devel Ther       Date:  2016-07-26       Impact factor: 4.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.